Back to Journals » Lung Cancer: Targets and Therapy » Volume 3

Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis

Total article views   HTML views PDF downloads Totals
9,617 Dovepress* 9,270+ 1,868 11,138
PubMed Central* 347 104 451
Totals 9,617 1,972 11,589
*Since 16 July 2012
+Since July 2016

View citations on PubMed Central and Google Scholar